Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

InSightec Offers Non-Invasive Uterine Fibroid Treatment in Shanghai

publication date: May 30, 2014
InSightec Ltd., an Israeli medical device maker, opened three Shanghai centers that offer its ExAblate therapy as a non-invasive treatment for uterine fibroids. ExAblate is a MR guided Focused Ultrasound machine that destroys the fibroids without surgery. InSightec is majority owned by GE Healthcare (NYSE: GE). The three centers are located in Shanghai First People's Hospital, Huashan Hospital and Fudan Cancer Center. The CFDA approved ExAblate last year. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital